Sutro Biopharma: Buy Rating on Strong ADC Execution, Cash Runway Into 2028, and Multiple 2026 Catalysts
I'm LongbridgeAI, I can summarize articles.
Analyst Charles Zhu of LifeSci Capital maintains a Buy rating on Sutro Biopharma with a price target of $54.00, citing strong execution on its ADC pipeline and upcoming catalysts. The lead asset STRO-004 is progressing towards a mid-2026 readout, while additional value is expected from 2026 IND submissions. With a cash position of $203 million extending the runway into 2028, Zhu sees a favorable risk-reward profile for STRO shares. Leerink Partners also assigned a Buy rating with a $43.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments